These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

754 related items for PubMed ID: 22210224

  • 1. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, Alawa CB, Alsaadi M, Mullen AB, Carter KC.
    Vaccine; 2012 Feb 08; 30(7):1357-63. PubMed ID: 22210224
    [Abstract] [Full Text] [Related]

  • 2. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
    Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC.
    J Parasitol; 2010 Oct 08; 96(5):929-36. PubMed ID: 20950100
    [Abstract] [Full Text] [Related]

  • 3. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection.
    Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, McFarlane E.
    Vaccine; 2007 May 30; 25(22):4502-9. PubMed ID: 17418459
    [Abstract] [Full Text] [Related]

  • 4. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK, Titus RG.
    Am J Trop Med Hyg; 2007 Mar 30; 76(3):579-84. PubMed ID: 17360887
    [Abstract] [Full Text] [Related]

  • 5. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 30; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 6. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N, Zahedifard F, Azizi H, Taslimi Y, Alonso MJ, Rafati S.
    Vaccine; 2008 Oct 29; 26(46):5822-9. PubMed ID: 18804512
    [Abstract] [Full Text] [Related]

  • 7. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, García-Miss Mdel R, Palatnik de Sousa CB, Dumonteil E.
    Infect Immun; 2005 Feb 29; 73(2):812-9. PubMed ID: 15664920
    [Abstract] [Full Text] [Related]

  • 8. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N, Jaffe CL.
    J Immunol; 1993 Mar 15; 150(6):2322-31. PubMed ID: 8450215
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S.
    Exp Parasitol; 2011 Mar 15; 127(3):627-36. PubMed ID: 21187087
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana.
    Rosado-Vallado M, Mut-Martin M, García-Miss Mdel R, Dumonteil E.
    Vaccine; 2005 Nov 16; 23(46-47):5372-9. PubMed ID: 16054271
    [Abstract] [Full Text] [Related]

  • 14. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease.
    Gicheru MM, Olobo JO, Anjili CO.
    Exp Parasitol; 1997 Feb 16; 85(2):109-16. PubMed ID: 9030661
    [Abstract] [Full Text] [Related]

  • 15. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
    Bras-Gonçalves R, Petitdidier E, Pagniez J, Veyrier R, Cibrelus P, Cavaleyra M, Maquaire S, Moreaux J, Lemesre JL.
    Infect Genet Evol; 2014 Jun 16; 24():1-14. PubMed ID: 24614507
    [Abstract] [Full Text] [Related]

  • 16. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
    Soto M, Corvo L, Garde E, Ramírez L, Iniesta V, Bonay P, Gómez-Nieto C, González VM, Martín ME, Alonso C, Coelho EA, Barral A, Barral-Netto M, Iborra S.
    PLoS Negl Trop Dis; 2015 May 16; 9(5):e0003751. PubMed ID: 25955652
    [Abstract] [Full Text] [Related]

  • 17. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 18. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R, Kaur S.
    Vaccine; 2010 May 21; 28(23):4002-12. PubMed ID: 20093205
    [Abstract] [Full Text] [Related]

  • 19. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
    Kaur J, Kaur T, Kaur S.
    Acta Trop; 2011 Jul 21; 119(1):50-6. PubMed ID: 21530477
    [Abstract] [Full Text] [Related]

  • 20. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S.
    Vaccine; 2009 Dec 10; 28(1):53-62. PubMed ID: 19818721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.